HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Nakaraang pagsara
$2.24
Sakop ng araw
$2.16 - $2.24
Sakop ng taon
$1.87 - $4.20
Market cap
19.18M USD
Average na Volume
30.80K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 70.00K | — |
Gastos sa pagpapatakbo | 4.94M | -10.59% |
Net na kita | -4.66M | 7.63% |
Net profit margin | -6.66K | — |
Kita sa bawat share | -0.54 | 11.48% |
EBITDA | -4.82M | 11.94% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 21.97M | -42.58% |
Kabuuang asset | 25.16M | -40.90% |
Kabuuang sagutin | 4.38M | -4.17% |
Kabuuang equity | 20.78M | — |
Natitirang share | 8.76M | — |
Presyo para makapag-book | 0.92 | — |
Return on assets | -44.96% | — |
Return on capital | -52.89% | — |
Cash Flow
Net change in cash
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -4.66M | 7.63% |
Cash mula sa mga operasyon | -3.96M | 25.12% |
Cash mula sa pag-invest | 505.00K | -95.69% |
Cash mula sa financing | 64.00K | 100.00% |
Net change in cash | -3.38M | -152.13% |
Malayang cash flow | -2.34M | 34.21% |
Tungkol
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Itinatag
1980
Headquarters
Website
Mga Empleyado
26
